$ USD
¥ 人民币
$ USD
€ 欧元
English
简体中文
English
繁体中文
Sign In / Sign up
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Menu
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Home
Oncology
Oncology
Oncology_Medical Halo Global Medical Oncology News_Oncology Drug Therapy News
瑞博西尼是否进入医保?
2025-10-19 11:44:20
Check Details
瑞博西尼多久起效?
2025-10-19 11:44:20
Check Details
患者使用瑞博西尼需要注意的事项
2025-10-19 11:44:20
Check Details
瑞博西尼是化疗药还是靶向药?
2025-10-19 11:44:20
Check Details
来那替尼什么价位?
2025-10-19 11:44:20
Check Details
FDA常规批准Sacituzumab Govitecan用于治疗不可切除性局部晚期或转移性三阴性乳腺癌
2025-10-19 11:44:20
Check Details
TAS-117治疗卵巢癌和乳腺癌具有一定疗效且安全性可控
2025-10-19 11:44:20
Check Details
Gedatolisib联合帕博西林治疗ER+/HER2-晚期乳腺癌缓解率可达60%
2025-10-19 11:44:20
Check Details
SDX-7320联合帕博西尼抑制乳腺癌异种移植物的肿瘤生长
2025-10-19 11:44:20
Check Details
乳腺癌放疗时可以服用卡培他滨吗?
2025-10-19 11:44:20
Check Details
阿贝西利可与氟维司群一起用于乳腺癌激素治疗后病情恶化的女性
2025-10-19 11:44:20
Check Details
阿贝西利适用于激素受体阳性(HR+)和HER2阴性(HER2-)的乳腺癌
2025-10-19 11:44:20
Check Details
1
2
...
1982
1983
1984
1985
1986
1987
1988
...
4153
4154
Category
Oncology
Hepatobiliary
dermatology
Endocrinology
Hematology
Andrology
Gynecology
Nephrology
Urology
Department of Infectious Diseases
Gastroenterology
Respiratory department
Neurology
Cardiology and Brain Department
ophthalmology
Psychiatry
Immunology Department
orthopedics
Burn Department
相关知识
1
Cabozantinib: Pivotal Advancements and Global Implications in Multi-Cancer Treatment with Multi-Kinase Inhibition
2
Tucatinib (Tukysa): A Precision Medicine for HER2-Positive Breast & Colorectal Cancer
3
Global Breakthrough: Pralsetinib - Precision Medicine for RET Mutation-Driven Cancers
4
Elacestrant: Precision Therapy for ESR1-Mutant Resistant HR+/HER2- Advanced Breast Cancer
5
Selpercatinib Complete Medication Guide: Indications, Dosage and Safety Information for RET Inhibitor
6
Complete Guide to Dosage and Dose Adjustment of Entrectinib
7
Comprehensive Analysis of Bleeding Risk with Tepotinib in MET-Mutated Non-Small Cell Lung Cancer
8
Lomustine vs Temozolomide: Comprehensive Comparison of Efficacy and Safety in Glioma Treatment
9
Tepotinib and Osimertinib: Current Status and Clinical Positioning of Combination Therapy in Non-Small Cell Lung Cancer
10
Tumor Shrinkage Effect and Core Therapeutic Value of Pazopanib
11
Tabrecta (Capmatinib): A Targeted Therapy for METex14-Mutated NSCLC
12
Pazopanib Shows Promise as Second-Line Therapy for Aggressive Skin Cancer